Azenta to Participate in the 9th Annual Evercore Healthcare Conference
Azenta, Inc. announced that its management team will participate in the 9th Annual Evercore Healthcare Conference on November 30, 2026.
Stocks · News reference
Rosen Law Firm is investigating potential securities claims on behalf of Azenta shareholders regarding allegations of misleading business information.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Azenta, Inc. announced that its management team will participate in the 9th Annual Evercore Healthcare Conference on November 30, 2026.
Needham analyst David Saxon maintained a Buy rating on Azenta and raised the price target from $37 to $57 following the company's recent financial results.
Azenta reported 5% year-over-year revenue growth for the fourth quarter of fiscal 2026 and provided fiscal 2027 revenue guidance ranging from $648 million to $660 million.
Filed: 2026-11-10 AccNo: 0001628280-26-072809 Size: 923 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Azenta, Inc. announced an exclusive licensing agreement with Elegen Corp. and the acquisition of SynPlexity Inc. to expand its GENEWIZ gene synthesis and library offerings.